Pharma Mar SA · BME:PHM

Pharma Mar SA — Investor Presentation (November 2022)

34 slides from Pharma Mar SA's investor presentation, November 2022

  1. Slide 1: Corporate Presentation

    November 2022 Corporate Presentation World leader in the development and commercialization of anticancer drugs of marine origin

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements that include information about possible or assumed future results of the business, financial condition, liquidity, results of operation, clinical program, plans and objectives of Pharma Mar, S.A. ("PharmaMar" or the "Company"). These f

  3. Slide 3: Management Team

    Management Team We are inspired by the sea, driven by science, and motivated to improve the lives of cancer patients by delivering novel medicines. We intend to continue to be the world leader in marine D. José María Fernández, Ph.D Luis Mora medicinal discovery, development and Chief Executive Offi

  4. Slide 4: Corporate Overview

    Corporate Overview Global Fully Integrated 3 Approved Oncology Commercial Stage Biotech Products Developing marine-inspired oncology drugs Established European oncology sales force Revenue Generating & Profitable Discovery Platform Strengthening Oncology Revenues in 2021 €230m Pipeline EBITDA 2021 €

  5. Slide 5: The Plan for Growth

    The Plan for Growth On Track to Deliver Value to Shareholders Lurbinectedin Other drugs Corporate development development development ✦ Phase 3 trial with Lurbinectedin ✦ Looking for in-licensing products ✦ 2 Phase 2 trials for Ecubectedin to market in EU in SCLC for EU approval enrolling and confir

  6. Slide 6: Pipeline – Expanding our Expertise in Oncology

    Pipeline – Expanding our Expertise in Oncology Phase 1 Phase 2 Phase 3 Market Soft tissue sarcoma 2nd/3rd line Monotherapy Ovarian cancer 2nd/3rd line + Doxil (PLD) R/R Multiple Myeloma1 3rd/4th line + dexamethasone Small cell lung cancer 2nd line US Monotherapy Small cell lung cancer Maintenance +

  7. Slide 7: Lurbinectedin - Novel Selective Inhibitor of Oncogenic Transcription

    Lurbinectedin - Novel Selective Inhibitor of Oncogenic Transcription Lurbinectedin binds preferentially within Transcription the promoter area of a selected group of Factors genes, in triplets: Lurbinectedin SWI/SNF SWI/SNF ARID1A ARID1A DNA RNA Pol II 5’-AGC-3’ 5’-CGG-3’ 5’-TGG-3’ 5’-AGG-3’ Harlow

  8. Slide 8: Lurbinectedin – Effects on the Immune System

    Lurbinectedin – Effects on the Immune System Lurbinectedin depletes the presence of TAMs in the tumor and inhibits the production of certain protumoral chemokines by them IL-6 TAMs VEGF IL-8 IL-8 CCL2 Inhibition of Tumor Cell IL-6 Induction of Proliferation angiogenesis Inhibition of Immune Response

  9. Slide 9: 1st FDA approved drug in over 24 years for relapsed SCLC

    SCLC 1st FDA approved drug in over 24 years for Relapsed Small Cell Lung Cancer (SCLC) New Standard of Care in 2L SCLC in the US 9

  10. Slide 10: Zepzelca: Transformative for PharmaMar

    Zepzelca: Transformative for PharmaMar License agreement in the US/Canada $200m received upfront ✦ 2021 sales = $46m royalties for PharmaMar $100m received approval ✦ High teens to 30% Royalties on US/Canada sales $25m received commercial milestone ✦ Initiated Phase 3 in 1L maintenance ES-SCLC in co

  11. Slide 11: Small Cell Lung Cancer (SCLC)

    Small Cell Lung Cancer (SCLC) SCLC An Underserved High Unmet Medical Need Among all Lung Cancers Low survival rate at 5 years Limited treatment options in both the US and Europe SCLC 15% ✦ Highly aggressive tumor 61,300 in 20182 ✦ 5-year survival rate 5-10%1 30,000 in 20182 Newly diagnosed patients

  12. Slide 12: Development Lagging Behind NSCLC

    Small Cell Lung Cancer (SCLC) SCLC Development Lagging Behind NSCLC 1st Line Cisplatin + Carboplatin + Durv or Atezo + Etoposide Etoposide Carboplatin + SCLC Etoposide 2nd Line Topotecan Pre - 1993 1996 24 years 2020 NSCLC 12

  13. Slide 13: Zepzelca – The SCLC Treatment Paradigm

    Zepzelca (Lurbinectedin) – The SCLC Treatment Paradigm SCLC Strong Positioning Opportunity 1st Line 2nd Line 3rd Line 1st Line 2nd Line 3rd Line • Platinum/ • Platinum/ Etoposide + • Zepzelca Etoposide + FDA EMA • Topotecan • Topotecan Approved • Atezolizumab Approved • Atezolizumab or Durvalumab (s

  14. Slide 14: Zepzelca Already Treatment of Choice in 2L SCLC

    Zepzelca Already Treatment of Choice in 2L SCLC SCLC With Significant Room to Grow Other; 4% I/O; 14% 37% % Market Share in 2L SCLC in the US 40 37% Topotecan; 8% 33 Non-platinum 25 Chemo; 9% 18 Platinum retreatment; 10 28% Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 1. Adapted from Jazz Pharmaceuticals

  15. Slide 15: Zepzelca Demonstrated Efficacy in Sensitive and Resistant SCLC

    Zepzelca Demonstrated Efficacy in Sensitive and Resistant SCLC Small Cell Lung Cancer patients In relapsed SCLC as monotherapy under accelerated approval based on Phase 2 monotherapy data1 Overall Resistant Sensitive Decrease in tumor size in 65% patients2 (n=105) CTFI< 90 days CTFI= 90 days (n=45)

  16. Slide 16: Low Rate of AEs and Manageable Hematological Safety Profile

    Zepzelca Already Treatment of Choice in 2L SCLC SCLC Low Rate of AEs and Manageable Hematological Safety Profile Despite Low Use of G-CSF 1,2 Safety: Related or Unknown Treatment Related (or Unknown) Adverse Events Adverse Events (AEs) ( >5% or Gr 3-4) Overall (n=105) n (%) Gr 1-2 Gr 3-4 Overall (n=

  17. Slide 17: Pathway to 2nd line in SCLC by EMA and Full Approval by FDA

    Zepzelca: Pathway to 2nd line in SCLC by EMA and Full Approval by FDA Phase 3 (LAGOON) randomized trial Arm A Lurbinectedin 3.2 mg/m2 every 3 weeks Primary Endpoint: ✦ Relapsed SCLC Arm B ✦ One prior platinum Randomization Overall Survival containing regimen 1:1:1 Arm A vs. C ✦ CTFI ≥30 days 705 pat

  18. Slide 18: 1st line-Maintenance Study in SCLC

    SCLC 1st line-Maintenance Study in SCLC 18

  19. Slide 19: Lurbinectedin-Atezolizumab combo in relapsed SCLC (PoC trial)

    Lurbinectedin-Atezolizumab combo in relapsed SCLC (PoC trial) • Phase I open label dose ranging trial in pts who had progressed on platinum. ECOG 0-1 • Full dose Atezo + L2.5mg/m2 (n=5) followed by L3.2mg/m2 (n=21, full dose) Response N=26 CR 8% (2) PR 50% (13) ORR 58% (15) SD 27% (6) DCR 85% PD 12%

  20. Slide 20: Lurbinectedin: First line positioning

    Lurbinectedin: First line positioning SCLC Phase 3 IMforte trial for First line-Maintenance SCLC Induction Phase Maintenance Phase Atezolizumab 1,200 mg q3wk + Lurbinectedin 3.2 mg/m2 q3wk ✦ Extensive-stage Endpoints: SCLC (ES-SCLC) Atezolizumab + Randomization ✦ Ongoing response Carboplatin + 1:1 ✦

  21. Slide 21: Strategic importance of Zepzelca Phase 3s in SCLC

    Strategic importance of Zepzelca Phase 3s in SCLC Potential treatment landscape after Phase 3s SCLC 1st Line- 1st Line- 1st Line 2nd Line 1st Line 2nd Line Mantenance Mantenance ✦ Platinum/ ✦ Platinum/ Etoposide + ✦Zepzelca ✦ Zepzelca Etoposide + ✦ Zepzelca + • Zepzelca FDA ✦ Topotecan EMA • Topotec

  22. Slide 22: Malignant Pleural Mesothelioma Finalizing Trial Strategy

    MPM Malignant Pleural Mesothelioma Finalizing Trial Strategy 22

  23. Slide 23: Zepzelca – Relapsed Malignant Pleural Mesothelioma

    Zepzelca (Lurbinectedin) – Relapsed Malignant Pleural Mesothelioma MPM A Rare Disease with limited available Therapeutic Options Aggressively growing tumor ~ 80% of cases related to asbestos exposure Incidence ~3,0001 patients diagnosed in the US per year Incidence and ~11,000 in Europe2 1st Line 2n

  24. Slide 24: Zepzelca – PFS Benefit in Malignant Pleural Mesothelioma

    Zepzelca (Lurbinectedin) – PFS Benefit in Malignant Pleural Mesothelioma Phase 2 Study1 MPM ✦ Primary endpoint PFS at 12 ✦ 42 patients progression weeks: on 1 prior platinum based ✦ Primary endpoint met therapy (p=0.015) Planning Phase 3 ✦ Lurbinectedin at 3.2 mg/m 2 ✦ mPFS 4.1 months every 3 weeks

  25. Slide 25: Leveraging Commercial Infrastructure in Europe

    European experience: Leveraging Commercial Infrastructure in Europe ✦ Strong KOL connections in solid tumors PharmaMar positioned as a partner of choice in Europe ✦ Navigation of EU, UK and CH regulators ✦ Logistics in place for distribution ✦ Expertise in multi-language labelling 18 Regional Partne

  26. Slide 26: Zepzelca (Lurbinectedin) – Intellectual property

    Zepzelca (Lurbinectedin) – Intellectual property Life cycle management plans under way 2022 2023 2024 2025 2026 2027 2028+ Orphan Drug Exclusivity in SCLC New Chemical Entity Composition of Matter Patent Potential 5 year extension to 2029 (filed) Orphan Drug Exclusivity in SCLC Composition of Matter

  27. Slide 27: Other opportunities

    Other opportunities 27

  28. Slide 28: Plitidepsin in SARS-CoV-2 Patients

    Plitidepsin in SARS-CoV-2 Patients ✦ SARS-CoV-2 cells co-opt EF1A from host to replicate ✦ Positive multi-center clinical trial ✦ Safety primary endpoint met for 3 doses ✦ Viral load and CRP reduced ✦ Pivotal Phase 3 ongoing (Neptuno / NCT04784559) 5nM plitidepsin HCoV-229E infected cells 1. Sources

  29. Slide 29: Plitidepsin in SARS-CoV-2 Patients: Phase 3 Study NEPTUNO 1

    Plitidepsin in SARS-CoV-2 Patients: Phase 3 Study NEPTUNO1 Adult Patients with Moderate Disease Hospitalized moderate COVID-19 adult pts requiring O2 supplementation n=203 plitidepsin 2.5mg IV per day dexamethasone 6mg/day patients + dexamethasone 8mg/day Primary endpoint: Time until n=203 plitideps

  30. Slide 30: Financials

    Financials Pharma May

  31. Slide 31: Financials

    Financials Well financed to support next stages of development Robust Cash Position (€m) Profitable (€m) 300 300 225 225 150 150 75 75 0 0 (75) (150) (75) 2018 2019 2020 2021 2018 2019 2020 2021 Debt Cash Revenues EBITDA 31

  32. Slide 32: Key Events

    Key Events Catalyst Calendar Lurbi Combo Atezo data presented at SITC Zepzelca approved in additional countries UAE, Singapore, Australia, Canada 2nd line Phase 3 SCLC trial initiation Ecubectedin “First Patient In” Phase 2 Potential first Zepzelca sales milestone Potential lurbinectedin approvals i

  33. Slide 33: Building the Next Phase of Growth

    Building the Next Phase of Growth 2021-2026 Strong Zepzelca Leveraging proven oncology drugs Intellectual in new indications and expanding Property into new territories Zepzelca expected Clinical data Solid financial capabilities to new approvals and launches in non-EMA IP 2022-25 broaden and accele

  34. Slide 34: www.pharmamar.com

    www.pharmamar.com. . a Dy i - 3 aA > = = aS - ae! ~

Pharma Mar — Investor Presentation (November 2022) on 6ix